MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.84
-0.17
-1.89%
After Hours: 8.84 0 0.00% 16:00 05/18 EDT
OPEN
9.00
PREV CLOSE
9.01
HIGH
9.14
LOW
8.82
VOLUME
435.91K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
6.70
MARKET CAP
901.46M
P/E (TTM)
-3.5749
1D
5D
1M
3M
1Y
5Y
Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that new preclinical and clinical data will be presented at upcoming medical meetings in June...
BusinessWire · 6d ago
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 05/10 09:24
Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop
Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81.
Benzinga · 05/07 19:03
Epizyme Inc Has Returned 24.4% Since SmarTrend Recommendation (EPZM)
May 07, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on November 6th, 2020 at $10.64. In...
marketwatch.com · 05/07 17:54
AUPH, MGI, EPZM and FROG among midday movers
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharm...
Seekingalpha · 05/07 16:38
Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide
Midway through trading Friday, the Dow traded up 0.45% to 34,705.48 while the NASDAQ rose 1.35% to 13,816.46. The S&P also rose, gaining 0.77% to 4,233.93.
Benzinga · 05/07 16:20
Regional Health Properties, Auris Medical leads healthcare gainers; ChemoCentryx, Orphazyme among major losers
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aurinia Pharmaceuticals (AUPH) ...
Seekingalpha · 05/07 15:04
Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April
Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68.
Benzinga · 05/07 14:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPZM. Analyze the recent business situations of Epizyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPZM stock price target is 18.63 with a high estimate of 36.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 232
Institutional Holdings: 105.18M
% Owned: 103.15%
Shares Outstanding: 101.98M
TypeInstitutionsShares
Increased
51
4.95M
New
18
1.77M
Decreased
40
8.87M
Sold Out
14
431.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Chief Scientific Officer
Jeffery Kutok
Other
Shefali Agarwal
Other
Matthew Ros
Director
Michael Giordano
Director
Pablo Legorreta
Independent Director
Andrew Allen
Independent Director
Kenneth Bate
Independent Director
Grant Bogle
Independent Director
Kevin Conroy
Independent Director
Carl Goldfischer
Independent Director
Victoria Richon
No Data
About EPZM
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.